

Abstract P287 Figure 1 Correlation between CRP and Citrulline concentration

Results In total there were 15 (10M) patients, aged 58(55-63) [median (range)] years. All had citrulline  $\leq 21~\mu$ mol/L (10 (5–18)). Faecal calprotectin and elastase were available in 87% and 67% and were 691 (445–2022) µg/g faeces and 217 (15-384) µg/g faeces respectively. The average PN days were 41 days including PN discontinuation due to end of life/palliative care (6(40%)). All had eGFR >60 (76->90) ml/min except one patient (20 ml/min) and CRP 35 (11–201) mg/L. A significant negative correlation was observed between CRP and citrulline concentrations (p=0.013). Plasma citrulline concentrations were 15 (5.4) vs. 5 (1.8) µmol/L (mean (SD)) (p<0.001) when CRP threshold for mild/moderate vs. severe sepsis is considered as 100 mg/L (figure 1).

Conclusion In our cohort, citrulline  $\sim$ 21  $\mu$ mol was a strong indicator of PN dependency in iGvHD. Thus, Citrulline has a useful clinical utility in the nutritional assessment of iGvHD patients. Larger studies are required to establish threshold for citrulline in septic iGvHD patients.

## REFERENCE

 Crenn P, Coudray-Lucas C, Thuillier F, Cyanober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal Failure in humans. *Gastroenterology* 2000; 119:1496–505.

## Colon and anorectum

P288

DOWNSTAGING OF RIGHT-SIDED COLORECTAL CANCER DIAGNOSED THROUGH IRON DEFICIENCY ANAEMIA

<sup>1,2</sup>Orouba Almilaji\*, <sup>2</sup>Sally Parry, <sup>1</sup>Peter Thomas, <sup>2</sup>Jonathon Snook. <sup>1</sup>Clinical Research Unit, Bournemouth University, Bournemouth, UK; <sup>2</sup>Gastroenterology Unit, Poole Hospital NHS Foundation Trust. UK

10.1136/gutjnl-2020-bsgcampus.362

Introduction Previous studies have suggested that iron deficiency anaemia (IDA) is an indicator of poor prognosis in colorectal cancer (CRC), but this may be due to confounding – IDA is much commoner in right-sided CRC, which tends to late presentation and therefore a worse prognosis. This study aims to determine the effect of diagnosing CRC through the detection of IDA on tumour stage - a surrogate marker of prognosis in CRC - whilst controlling for tumour side.

Methods A total of 1154 cases of CRC with adequate clinical information were identified from the MDT records of a single general hospital for 2010–2016. Histological confirmation of

adenocarcinoma was available in 90%. Each case was staged on the basis of the available radiological and surgical evidence, and the route of presentation identified. Because tumour side and presentation are surrogate markers of prognosis in CRC, these variables were merged to create a new variable to reflect CRC prognosis, and analysed using binary logistic regression models.

Results A summary of the basic patient data is shown in table 1. As anticipated, most cases presenting with IDA proved to have right-sided tumours, whilst the majority of cases diagnosed through screening were left-sided.

As expected, left-sided tumours diagnosed through screening (mostly in the national bowel cancer screening programme) were significantly down-staged in comparison to those presenting with symptomatic disease – with an odds ratio for early stage disease of 2.09 (95% CI 1.4 - 3.1, P<0.001).

The key finding in this study is that right-sided tumours diagnosed following the detection of IDA also appear to be down-staged compared to those presenting with symptomatic disease – with an odds ratio for early stage disease of 2.52 (95% CI 1.6 - 3.8, P<0.0001).

	IDA	Screening	Symptomatic	Overall
Number	171	213	770	1154
Sex ratio - M/F	1.1	1.5	1.3	1.3
Age (years) – mean (sd)	77 (± 11)	68 (± 6)	73 (± 13)	72 (± 12)
Hb (g/l) - mean (sd)	88 (± 17)	133 (± 19)	122 (± 23)	119 (± 25
Early stage (I or II) - n	89 (52.0%)	127	304 (39.5%)	520
(%)		(59.6%)		(45.1%)
Right-sided – n (%)	141	71 (33.3%)	243 (31.6%)	455
	(82.5%)			(39.4%)

Conclusion The findings suggest a prognostic benefit to diagnosing right-sided CRC through the detection of IDA, with a benefit comparable to that of the screening programme for left-sided CRC. This strengthens the case for a systematic approach to blood count monitoring in the population at-risk of CRC.

P289

## THE EXTENT AND IMPACT OF RADIATION PROCTOPATHY: A CASE SERIES OF PELVIC RADIATION DISEASE PATIENTS

Nasar Aslam\*, Andrea Au, Tom Barnes, Johannah Cook, Caroline Henson. *University Hospital of South Manchester NHS Foundation Trust, Manchester, UK* 

10.1136/gutjnl-2020-bsgcampus.363

Introduction Radiation proctopathy (RP) is a common diagnosis following pelvic radiotherapy and can lead to debilitating symptoms of rectal bleeding, bowel urgency, tenesmus and passage of rectal mucus. Current data suggest 6% of patients have severe rectal bleeding that can negatively impact on quality of life.

There are limited data on the prevalence of RP in patients following pelvic radiotherapy, its symptom profile and its management. Here we report a large case series from a tertiary pelvic radiation disease clinic.

A190 Gut 2021;**70**(Suppl 1):A1–A262